Nanolattix Chairman Qu Zhican Visits China Energy Silk Road Chairman Cheng Yuan to Explore New Global Pathways for the Pharmaceutical and Health Industry
Release time:
2025-10-10
On September 23, 2025, Dr. Qu Zhican, Chairman of Nanolattix, visited Beijing for a high-level meeting with Mr. Cheng Yuan, Chairman of China Energy Silk Road Technology Industry (Beijing) Co., Ltd. The two sides engaged in in-depth discussions on global trends and collaboration opportunities in the biopharma and healthcare industries, with a particular focus on investment prospects in anti-cancer drugs and strategies for expanding health products in the international market.
During the meeting, Dr. Qu Zhican highlighted Nanolattix’s core strengths in the industrial application of plant-derived active ingredients. Leveraging the HENTech nano-plant extraction platform, Nanolattix has been intensively developing specialty plant resources from Shanxi Province, establishing a diverse portfolio of health products across multiple sectors. In addition, the company is actively advancing a series of ADC/RDC biopharmaceutical R&D pipelines, with its core anti-cancer drug T320 as a key representative. Nanolattix also plans to expand investment in this field and looks forward to deepening collaboration with China Energy Silk Road to explore new pathways for the global expansion of "Innovated in China" products in the healthcare sector.
Chairman Cheng Yuan of China Energy Silk Road expressed strong appreciation for Nanolattix’s technological expertise and product strategy in the pharmaceutical and health industries. He introduced China Energy Silk Road as an industrial platform dedicated to advancing new quality productive forces and serving Belt and Road markets. With extensive local operation experience and investment channels across multiple countries and regions, the company is well-positioned to provide support in technology commercialization, project financing, and cross-border operations. Both sides agreed that by integrating resources and pursuing coordinated investments, they can facilitate the global reach of more health products with Chinese characteristics.
This high-level meeting laid a solid foundation for further collaboration between the two parties. Nanolattix will continue to embrace open cooperation, deepening ties with high-quality partners across the industrial chain, including China Energy Silk Road. Driven by both technology and capital, the company will focus on accelerating the R&D and global commercialization of green health products and innovative anti-cancer drugs, aiming to deliver health solutions from China to the world.
Tag:
recommend News
Share
